This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
Exelixis (EXEL), BioInvent Tie Up for Immuno-Oncology Therapies
by Zacks Equity Research
Exelixis (EXEL) looks to expand its biotherapeutics development pipeline by using BioInvent's proprietary immuno-oncology screening platform and antibody library.
BMYPositive Net Change GERNNegative Net Change ALKSNegative Net Change EXELPositive Net Change
biotechnology biotechs pharmaceuticals
National Health Investors (NHI) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
NHINegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Chico's FAS (CHS) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
CHSPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Biotech Stock Roundup: BLUE Up on Regulatory Updates, RIGL's Pipeline News & More
by Zacks Equity Research
Regulatory and other updates from bluebird (BLUE) and Rigel (RIGL) are a few key highlights from the biotech sector during the past week.
RIGLNegative Net Change COGTPositive Net Change VALNPositive Net Change
biotechnology biotechs pharmaceuticals
Valneva (VALN) Down on its COVID-19 Vaccine Update in Europe
by Zacks Equity Research
Valneva (VALN) slides on a proposed remediation plan update after receiving the European Commission's notice of intent to terminate the Advance Purchase Agreement for its COVID-19 vaccine.
PFEPositive Net Change GERNNegative Net Change ALKSNegative Net Change VALNPositive Net Change
biotechnology pharmaceuticals
Pyxis Tankers Inc. (PXS) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
PXSPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Bristol Myers (BMY) Up 20.4% YTD: Will the Momentum Continue?
by Zacks Equity Research
Bristol Myers (BMY) has put up an impressive performance so far in 2022, and the momentum should continue.
BMYPositive Net Change MRKPositive Net Change ALKSNegative Net Change TPTXNegative Net Change
biotechnology biotechs pharmaceuticals
Company News for Jun 13, 2022
by Zacks Equity Research
Companies In The News Are: DOCU, COGT, BA, SFIX.
BANegative Net Change COGTPositive Net Change SFIXPositive Net Change DOCUNegative Net Change
aerospace biotechnology business-services retail
4 Biotech Stocks With Bright Prospects to Buy Amid Recovery
by Zacks Equity Research
New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position ALKS, GERN, IMCR and BLU well amid the volatility.
GERNNegative Net Change ALKSNegative Net Change IMCRNegative Net Change
biotechnology biotechs pharmaceuticals
Will Health Revenue Growth Buoy Jabil (JBL) Q3 Earnings?
by Zacks Equity Research
Jabil (JBL) is expected to have recorded year-over-year higher revenues, driven by solid demand in key end markets, diligent execution of operational plans and skillful management of supply chain dynamics.
DALNegative Net Change KRNegative Net Change JBLPositive Net Change CMCNegative Net Change
biotechnology
Rigel (RIGL) wAIHA Study Fails to Meet Goals, Stock Tanks
by Zacks Equity Research
Rigel (RIGL) phase III study evaluating fostamatinib in patients with warm autoimmune hemolytic anemia did not demonstrate statistical significance in the primary efficacy endpoint.
GERNNegative Net Change LLYPositive Net Change ALKSNegative Net Change RIGLNegative Net Change
biotechnology pharmaceuticals
Roche (RHHBY) Gets EU Nod for Lunsumio, Tecentriq Label Expansion
by Zacks Equity Research
Roche (RHHBY) obtains EU approval for Lunsumio for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL) and label expansion of Tecentriq.
RHHBYPositive Net Change BMYPositive Net Change MRKPositive Net Change
biotechnology pharmaceuticals
The Zacks Analyst Blog Highlights Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics
by Zacks Equity Research
Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics are part of Zacks top Analyst Blog.
REGNNegative Net Change BMYPositive Net Change NVAXPositive Net Change MRTXPositive Net Change TPTXNegative Net Change
biotechnology medical pharmaceuticals
Biotech Stock Roundup: BMY's Acquisition, REGN to Buy Libtayo & More
by Zacks Equity Research
Acquisition and other updates from Bristol Myers (BMY) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.
REGNNegative Net Change BMYPositive Net Change NVAXPositive Net Change MRTXPositive Net Change TPTXNegative Net Change
biotechnology biotechs pharmaceuticals
Mirati (MRTX) Up on Positive Data From NSCLC Study on Adagrasib
by Zacks Equity Research
Mirati (MRTX) gains on positive results from an early stage KRYSTAL-1 study on experimental candidate adagrasib for lung cancer.
GERNNegative Net Change AMGNNegative Net Change ALKSNegative Net Change MRTXPositive Net Change
biotechnology biotechs pharmaceuticals
Intercept (ICPT) Announces Delay in Meeting With the FDA
by Zacks Equity Research
Intercept (ICPT) faces yet another setback as its resubmission for NDA for OCA for NASH gets delayed.
PFEPositive Net Change ALKSNegative Net Change ICPTPositive Net Change VKTXNegative Net Change
biofuels biotechnology
Bristol Myers (BMY) to Acquire Turning Point, Withdraws sBLA
by Zacks Equity Research
Bristol Myers (BMY) is set to acquire Turning Point to bolster its oncology portfolio. The company also withdraws its sbLA for Reblozyl.
BMYPositive Net Change MRKPositive Net Change ALKSNegative Net Change TPTXNegative Net Change
biotechnology
Par Petroleum (PARR) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
PARRPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Regeneron (REGN) to Buy Sanofi's Stake in Libtayo, Stock Down
by Zacks Equity Research
Regeneron (REGN) will obtain global rights to Libtayo from Sanofi in exchange for an upfront payment of $900 million and royalties.
REGNNegative Net Change SNYPositive Net Change BMYPositive Net Change MRKPositive Net Change
biotechnology pharmaceuticals
Caleres Inc. (CAL) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
CALNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Radius (RDUS) to Stop Work on Abaloparatide Transdermal System
by Zacks Equity Research
Radius Health (RDUS) will pause all work on the abaloparatide transdermal system based on regulatory clarity, timeline and costs.
GERNNegative Net Change LLYPositive Net Change AMGNNegative Net Change
biotechnology pharmaceuticals
Biotech Stock Roundup: BMY's Opdivo Updates, Pipeline Updates From REGN, BIIB
by Zacks Equity Research
Regulatory and pipeline updates from Regeneron (REGN) and Biogen (BIIB) are a few key highlights from the biotech sector during the past week.
REGNNegative Net Change SNYPositive Net Change BIIBPositive Net Change BMYPositive Net Change
biotechnology biotechs
Bristol Myers' (BMY) Opdivo Combos Get FDA Nod for ESCC
by Zacks Equity Research
Bristol Myers (BMY) secures an FDA approval for two Opdivo-based regimens as the first-line treatment of unresectable advanced or metastatic esophageal squamous cell carcinoma.
BMYPositive Net Change MRKPositive Net Change GERNNegative Net Change ALKSNegative Net Change
biotechnology pharmaceuticals
Northwest Pipe Co. (NWPX) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
NWPXNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Exelixis (EXEL) Announces Results From Phase II HNSCC Study
by Zacks Equity Research
Exelixis (EXEL) phase II study evaluating Cabometyx in combination with Keytruda in patients with recurrent or metastatic head and neck squamous cell carcinoma meets primary goal.
BMYPositive Net Change MRKPositive Net Change EXELPositive Net Change
biotechnology pharmaceuticals